• Exchange: Copenhagen
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech


209.0000 DKK 1.2000 0.58%

As of 11:02:35 ET on 07/22/2014.

Snapshot for Genmab A/S (GEN)

Open: 207.5000 Day's Range: 206.6000 - 209.5000 Volume: 124,377
Previous Close: 207.8000 52wk Range: 156.2000 - 260.0000 1-Yr Rtn: +18.01%

Stock Chart for GEN

No chart data available.
  • GEN:DC 209.0000
  • 1D
  • 1M
  • 1Y
Interactive GEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GEN

Current P/E Ratio (ttm) 80.5595
Estimated P/E(12/2014) 63.4872
Relative P/E vs. KFX 3.4947
Earnings Per Share (DKK) (ttm) 2.5944
Est. EPS (DKK) (12/2014) 3.2920
Est. PEG Ratio -
Market Cap (M DKK) 11,847.64
Shares Outstanding (M) 56.69
30 Day Average Volume 152,864
Price/Book (mrq) 6.1317
Price/Sale (ttm) 14.4765
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/13/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GEN

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GEN

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil